Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

8.92 EUR

-1.33 %

5,642 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-1.33 %
-11.68 %
-37.18 %
-35.83 %
-30.04 %
+11.50 %
+154.13 %
+35.15 %
-98.53 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
64.34M EUR
Turnover
13.63K EUR
P/E (adj.) (26e)
63.56
EV/EBIT (adj.) (26e)
55.4
P/B (26e)
12.32
EV/S (26e)
5.26
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.50 EUR
Updated
26.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 27.02.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
30.3
2026

General meeting '26

14.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Nexstim’s NBS System 6 gains FDA clearance for treatment of Obsessive Compulsive Disorder (OCD) Press release, Helsinki, 23 March 2026 at 10:30 AM (EET) Nexstim’s NBS System 6 gains FDA clearance for treatment of Obsessive Compulsive Disorder (OCD) Nexstim Plc (“Nexstim” or “Company...
3/23/2026, 8:33 AM
by Kyhnykeisari
35
Several competitors’ devices have already been able to treat OCD, so there are clear practices for it. This new approval just brings more versatile use for Nexstim’s therapy device. In itself, the company’s disclosure policy on future approvals is interesting and understandable in...
3/23/2026, 9:25 AM
by Kyhnykeisari
21
Nexstim’s NBS System 6 gains FDA clearance for treatment of Adolescent Depression Press release, Helsinki, 23 March 2026 at 1 PM (EET) Nexstim’s NBS System 6 gains FDA clearance for treatment of Adolescent Depression Nexstim Plc (“Nexstim” or “Company”) announces the launch of the...
3/23/2026, 11:02 AM
by Kyhnykeisari
20
Here are Antti’s comments on Nexstim’s marketing authorizations. Nexstim announced on Monday that it had received marketing authorization from the US Food and Drug Administration (FDA) for its NBS 6 system as an add-on treatment for obsessive-compulsive disorder (OCD) and for the...
3/24/2026, 5:52 AM
by Sijoittaja-alokas
10
For now, MRI scans have played a very important role in ensuring that the treatment is precisely targeted to the correct area. By stimulating the correct area, the treatment is also more effective. Treatments given with competitors’ devices do not hit the right spot as precisely,...
3/23/2026, 11:13 AM
by Kyhnykeisari
8
In this video, at the three-minute mark, they talk about Nexstim’s disposable head localizers and mandatory head MRI scans. The doctor in the video did not purchase the Nexstim device for the aforementioned reasons, but states in the video that Nexstim is giving up both of them. ...
3/23/2026, 11:05 AM
by MagnificRat
7
Interesting opening. Here is some statistical information about OCD (not verified, asked from AI): How many patients? Approximately 1.2% of adults suffer from OCD annually This corresponds to roughly 2–3 million adults in the United States Approximately 2.3% of the population experiences...
3/23/2026, 8:50 AM
by AccionHombre
6
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.